Cargando…
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-e...
Autores principales: | Houston, S J, Plunkett, T A, Barnes, D M, Smith, P, Rubens, R D, Miles, D W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362250/ https://www.ncbi.nlm.nih.gov/pubmed/10098763 http://dx.doi.org/10.1038/sj.bjc.6690196 |
Ejemplares similares
-
Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011) -
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016) -
c-erbB-4 protein expression in human breast cancer
por: Kew, T Y, et al.
Publicado: (2000) -
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013) -
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)